Less may be more: smaller lung surgery tested against standard removal

NCT ID NCT07169903

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This study compares two types of surgery for people with a specific kind of lung cancer (adenocarcinoma) that is 2-3 cm in size and has a low-to-intermediate grade. One surgery removes just the part of the lung with the tumor (segmentectomy), while the other removes an entire lobe (lobectomy). The goal is to see if the smaller surgery works just as well at preventing the cancer from coming back, while possibly helping patients keep more lung function. About 587 participants will be followed for 5 years after surgery.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
surgery (segmentectomy or lobectomy)
What this could lead to
If successful, this could show that a less extensive surgery (segmentectomy) is as effective as a larger one (lobectomy) for certain lung cancers, potentially preserving more lung function and improving recovery.
What could go wrong
This is a Phase 3 trial, but results are years away. The benefit may be small or not apply to all patients. Surgery always carries risks like infection or complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.